S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression: S100a9 deficiency accelerates tumor escape

In recent studies, the tolerable safety profile and positive bone marrow (BM) response suggest a beneficial use of anti-PD-1 agents in the treatment of Myelodysplastic Syndromes (MDS), but the underlying mechanism is still unknown. MDS is mainly characterized by ineffective hematopoiesis, which may...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Roujia, Zhao, Youshan, Li, Zijuan, Guo, Juan, Zhao, Sida, Song, Luxi, Wu, Dong, Wang, Lan, Chang, Chunkang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157523/
https://www.ncbi.nlm.nih.gov/pubmed/36810783
http://dx.doi.org/10.3724/abbs.2023015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157523/
https://www.ncbi.nlm.nih.gov/pubmed/36810783
http://dx.doi.org/10.3724/abbs.2023015

Ejemplares similares